Taysha Gene Therapies, Inc.
TSHA
$1.24
$0.065.09%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -89.30M | -22.77M | -114.34M | -118.01M | -111.57M |
Total Depreciation and Amortization | 1.25M | 1.31M | 1.34M | 1.37M | 1.37M |
Total Amortization of Deferred Charges | -- | 867.00K | 867.00K | 867.00K | 867.00K |
Total Other Non-Cash Items | 19.30M | -43.72M | 52.96M | 55.86M | 54.32M |
Change in Net Operating Assets | -12.47M | -14.71M | -16.20M | -12.72M | -18.01M |
Cash from Operations | -81.23M | -79.03M | -75.37M | -72.63M | -73.02M |
Capital Expenditure | -374.00K | -393.00K | -358.00K | -109.00K | -3.87M |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 11.00K | 7.00K | -3.48M | -3.48M | -3.48M |
Cash from Investing | -363.00K | -386.00K | -3.84M | -3.59M | -7.35M |
Total Debt Issued | -- | 39.55M | 39.55M | 39.55M | 39.55M |
Total Debt Repaid | -- | -43.00M | -43.00M | -43.00M | -43.00M |
Issuance of Common Stock | 77.23M | 77.23M | 211.24M | 141.26M | 141.28M |
Repurchase of Common Stock | -360.00K | -423.00K | -423.00K | -423.00K | -423.00K |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -185.00K | -563.00K | -533.00K | -643.00K | -1.02M |
Cash from Financing | 76.68M | 72.79M | 206.83M | 136.74M | 136.39M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -4.90M | -6.63M | 127.62M | 60.52M | 56.02M |